Treatment
Filgrastim clinical trials
We’re tracking 35 recruiting studies that include Filgrastim, each written for real people, not researchers, below.
Recruiting studies
- NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT06926751RecruitingPhase 2
Preventing low white blood cell counts in kids with solid tumors
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
BeijingAges 6–24 - NCT06023641RecruitingPhase 2
Liposomal irinotecan for children with rhabdomyosarcoma
This trial tests a new way to treat rhabdomyosarcoma using a targeted drug (liposomal irinotecan) based on the tumor's genetic makeup and risk group. It aims to improve outcomes for children and young adults with intermediate or high-risk disease.
Palo Alto, CaliforniaAges Up to 22 years - NCT00785525RecruitingPhase 3
G-CSF to collect stem cells from unrelated donors
This Phase 3 study tests using filgrastim (a medicine that helps stem cells leave the bone marrow) to collect stem cells from unrelated donors for transplant. It focuses on donor safety and whether this collection method works well enough for transplantation.
Boca Raton, FloridaAges 18–60 - NCT00801489RecruitingPhase 2
New treatment for AML or high-risk MDS using combination chemo
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
Houston, TexasAges 18 years+ - NCT01624805RecruitingPhase 2
Immunosuppressant treatment to help low blood counts in some bone marrow disorders
This trial tests a group of immune-suppressing medicines (with steroids and growth-factor injections) for people with aplastic anemia or certain low-risk myelodysplastic syndromes. The goal is to improve bone marrow function and reduce problems caused by low blood counts, such as fatigue, infections, or bleeding.
Houston, TexasAges 18 years+ - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT06381661RecruitingPhase 2
Personalized treatment for sepsis in children and adults
This trial is testing several different treatments to find the best one for each person with sepsis. It looks at specific 'treatable traits' like inflammation, blood clotting problems, or immune system issues to match you with the right therapy. The goal is to improve recovery and survival.
DijonAges 9 months+ - NCT04684368RecruitingPhase 2
New treatment study for children and young adults with NGGCT brain tumors
This Phase 2 study tests a new treatment approach for certain brain tumors called NGGCT in children and young adults. It may help improve outcomes by targeting tumors in specific brain locations and using tumor marker tests to guide care.
Birmingham, AlabamaAges 3–29 - NCT02015013RecruitingPhase 2
Blood cell collection study for immune system disorders
This study collects blood-forming cells from people with low CD4 counts and healthy volunteers to learn how the immune system works. It may help researchers better understand and treat conditions like idiopathic CD4 lymphocytopenia.
Bethesda, MarylandAges 18–65 - NCT04022239RecruitingPhase 1/Phase 2
Bendamustine to prevent transplant immune complications
This early-phase study tests whether giving the drug bendamustine (with or without another chemo drug) can lower the risk of graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is an immune reaction where the donor’s cells attack your body. If it works and is safe, it could improve outcomes after transplant.
Houston, TexasAges 18–70 - NCT06414889RecruitingPhase 1
Collecting stem cells safely in RUNX1 platelet disorder
This study tests the safety of collecting your own blood stem cells (called CD34+ cells) using a process called apheresis. It is for people with RUNX1 familial platelet disorder who may need a stem cell transplant in the future.
Houston, TexasAges 18–75 - NCT06188676RecruitingPhase 3
Nivolumab with chemotherapy for newly diagnosed PMBL
This trial tests a fixed low dose of nivolumab combined with standard chemo-immunotherapy for people newly diagnosed with primary mediastinal B-cell lymphoma. The goal is to see if this combination is safe and effective.
MoscowAges 18–70 - NCT06325709RecruitingPhase 1/Phase 2
Gene editing trial for X-linked chronic granulomatous disease
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
Bethesda, MarylandAges 18–75 - NCT07616154RecruitingPhase 2
Gene-Matched Family Stem Cell Transplant for Severe Sickle Cell
This trial tests whether a stem cell transplant from a partially gene-matched family member can cure severe sickle cell disease in children and young adults. The transplant uses a new approach that may work even when a perfectly matched sibling isn't available, and it might help patients whose sickle cell is causing serious complications like strokes, organ damage, or frequent pain crises.
Memphis, TennesseeAges Up to 22 years - NCT03214562RecruitingPhase 1/Phase 2
Venetoclax plus chemotherapy for acute leukemia
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Houston, TexasAges 18 years+ - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04224558RecruitingPhase 1/Phase 2
Stem cell transplant for hard-to-control Crohn’s disease
This early-phase study tests whether a stem cell transplant can improve Crohn’s disease in teens and young adults whose disease is active and not responding to standard medicines. It may help some people who are not doing well despite several prior treatments, but it also involves intensive study procedures and safety checks.
Los Angeles, CaliforniaAges 13–28 - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04959175RecruitingPhase 1/Phase 2
Lower post-transplant drug doses for older or unfit patients
This trial tests whether giving a lower dose of cyclophosphamide after a bone marrow transplant can be safer for older or medically “unfit” patients, while still helping control blood cancers. It is designed for people who can’t tolerate the usual strongest transplant preparation.
Bethesda, MarylandAges 12–85 - NCT05052957RecruitingPhase 2
Autologous stem cell rescue for newly diagnosed brain tumor
This trial tests giving a patient’s own stem cells back to help the bone marrow recover after treatment for newly diagnosed glioblastoma or gliosarcoma. It may help reduce blood-count problems so treatment can be given more safely.
Cleveland, OhioAges 18–75 - NCT05317403RecruitingPhase 1
Venetoclax plus chemo to change cancer cell behavior
This Phase 1 trial tests whether venetoclax, combined with chemotherapy and a “cancer cell behavior” medicine strategy, can improve treatment for people with AML that has come back or not gone into remission. It’s mainly looking at safety and early signs of benefit.
Milwaukee, WisconsinAges 1–25 - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT05535166RecruitingPhase 2
Risk- and lab-guided treatment for young children with medulloblastoma
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
Palo Alto, CaliforniaAges Up to 4.9 years
What Filgrastim is being studied for
Conditions with recruiting Filgrastim studies.
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- de Novo Myelodysplastic Syndrome
- High Risk Myelodysplastic Syndrome
- Myelodysplastic Syndrome With Excess Blasts
- Aplastic Anemia
- Previously Treated Myelodysplastic Syndrome
- Hematopoietic and Lymphoid System Neoplasm
- Acute Leukemia
- Acute Lymphoblastic Leukemia
Common questions
- Are there clinical trials studying Filgrastim?
- Yes. Clin2 currently lists 35 recruiting studies that include Filgrastim, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Filgrastim trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Filgrastim an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Filgrastim or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.